Loading…

Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain

Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is know...

Full description

Saved in:
Bibliographic Details
Published in:Neuroscience 2006-01, Vol.140 (4), p.1277-1287
Main Authors: Terry, A.V., Gearhart, D.A., Mahadik, S.P., Warsi, S., Waller, J.L.
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3
cites cdi_FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3
container_end_page 1287
container_issue 4
container_start_page 1277
container_title Neuroscience
container_volume 140
creator Terry, A.V.
Gearhart, D.A.
Mahadik, S.P.
Warsi, S.
Waller, J.L.
description Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is known about their effects on the densities of these receptors when they are administered for extended periods of time (a common practice in the clinical setting). In the present study in rats, the residual effects of prior chronic exposure to representative first generation antipsychotics and second generation antipsychotics on the densities of high affinity nicotinic acetylcholine receptors and muscarinic acetylcholine receptor in the brain were investigated. Test subjects were treated with the first generation antipsychotics, haloperidol (2.0 mg/kg/day) or chlorpromazine (10.0 mg/kg/day) or the second generation antipsychotics, risperidone (2.5 mg/kg/day) or olanzapine (10.0 mg/kg/day) in drinking water for periods of 90 or 180 days, given a drug-free washout period (i.e. returned to normal drinking water) for two weeks and then killed. Quantitative receptor autoradiography was subsequently performed using 16 μm sagittal slices of whole brain incubated with [ 3H]-epibatidine, [ 3H]-pirenzepine or [ 3H]-AFDX-384 to measure high affinity nicotinic acetylcholine receptors, M 1 and M 2 muscarinic acetylcholine receptors, respectively. The most notable experimental result was a moderate, but significant ( P
doi_str_mv 10.1016/j.neuroscience.2006.03.011
format article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68602118</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0306452206003782</els_id><sourcerecordid>68602118</sourcerecordid><originalsourceid>FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3</originalsourceid><addsrcrecordid>eNqNkc2O1DAQhCMEYoeFV0AWEtwy-C9Osjc0LD_SSlzgbDmd9sajjD3YDmiehxfFw0RabuBLy9LXVa2qqnrF6JZRpt7utx6XGBI49IBbTqnaUrGljD2qNqxrRd02Uj6uNlRQVcuG86vqWUp7Wl4jxdPqiinFVQE31a_dFIN3QHJEkw_oM_np8kSsiymTEElCCH4k9-gxmuyCJ8Znd0wnmEJ2kIjzJIaxLKYbcmstQk6kUJO7n4ix1nmXT6Q4FPrsY4rYYUlg4uULmE9z0ZqdRxIR8JhD_KOaJyRDNM4_r55YMyd8sc7r6tuH26-7T_Xdl4-fd-_uapCiz7VCYGLkPXZ9K6DhILnFHgbbSjuC7Ax2RnSqHxhyNjQDiLZvFUcLncKht-K6enPRPcbwfcGU9cElwHk2HsOStOoU5Yx1_wRZy4VkTV_AmwsIpa4U0epjdAcTT5pRfe5S7_XfXepzl5oKXbosyy9Xl2U44PiwupZXgNcrYEqes43Gg0sPXNsrJuX53PcXDkt4PxxGvdqNrgSe9Rjc_9zzGxUGyWY</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17234159</pqid></control><display><type>article</type><title>Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain</title><source>ScienceDirect Freedom Collection 2022-2024</source><creator>Terry, A.V. ; Gearhart, D.A. ; Mahadik, S.P. ; Warsi, S. ; Waller, J.L.</creator><creatorcontrib>Terry, A.V. ; Gearhart, D.A. ; Mahadik, S.P. ; Warsi, S. ; Waller, J.L.</creatorcontrib><description>Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is known about their effects on the densities of these receptors when they are administered for extended periods of time (a common practice in the clinical setting). In the present study in rats, the residual effects of prior chronic exposure to representative first generation antipsychotics and second generation antipsychotics on the densities of high affinity nicotinic acetylcholine receptors and muscarinic acetylcholine receptor in the brain were investigated. Test subjects were treated with the first generation antipsychotics, haloperidol (2.0 mg/kg/day) or chlorpromazine (10.0 mg/kg/day) or the second generation antipsychotics, risperidone (2.5 mg/kg/day) or olanzapine (10.0 mg/kg/day) in drinking water for periods of 90 or 180 days, given a drug-free washout period (i.e. returned to normal drinking water) for two weeks and then killed. Quantitative receptor autoradiography was subsequently performed using 16 μm sagittal slices of whole brain incubated with [ 3H]-epibatidine, [ 3H]-pirenzepine or [ 3H]-AFDX-384 to measure high affinity nicotinic acetylcholine receptors, M 1 and M 2 muscarinic acetylcholine receptors, respectively. The most notable experimental result was a moderate, but significant ( P&lt;0.01) increase in [ 3H]-AFDX-384 binding sites in a number of brain regions (including cortex, hippocampus, subiculum, substantia innominata, and thalamus) associated with prior exposure to olanzapine for 90, but not 180 days. Olanzapine was also associated with a significantly higher density of [ 3H]-pirenzepine binding sites in cortex lamina I after 90 days of prior drug exposure. These data indicate that chronic treatment with a commonly used second generation antipsychotic, olanzapine is associated with modest increases in M 2 muscarinic acetylcholine receptors in memory-related brain regions that may eventually abate with longer periods of chronic drug exposure.</description><identifier>ISSN: 0306-4522</identifier><identifier>EISSN: 1873-7544</identifier><identifier>DOI: 10.1016/j.neuroscience.2006.03.011</identifier><identifier>PMID: 16626873</identifier><identifier>CODEN: NRSCDN</identifier><language>eng</language><publisher>Oxford: Elsevier Ltd</publisher><subject>Animals ; Antipsychotic Agents - administration &amp; dosage ; Biological and medical sciences ; Brain - drug effects ; Brain - metabolism ; chlorpromazine ; cognition ; Fundamental and applied biological sciences. Psychology ; haloperidol ; Male ; Medical sciences ; Neuropharmacology ; olanzapine ; Pharmacology. Drug treatments ; Protein Binding - drug effects ; Protein Binding - physiology ; Psycholeptics: tranquillizer, neuroleptic ; Psychology. Psychoanalysis. Psychiatry ; Psychopharmacology ; Rats ; Rats, Wistar ; Receptors, Muscarinic - metabolism ; Receptors, Nicotinic - metabolism ; risperidone ; schizophrenia ; Vertebrates: nervous system and sense organs</subject><ispartof>Neuroscience, 2006-01, Vol.140 (4), p.1277-1287</ispartof><rights>2006 IBRO</rights><rights>2006 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3</citedby><cites>FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&amp;idt=17961448$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16626873$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Terry, A.V.</creatorcontrib><creatorcontrib>Gearhart, D.A.</creatorcontrib><creatorcontrib>Mahadik, S.P.</creatorcontrib><creatorcontrib>Warsi, S.</creatorcontrib><creatorcontrib>Waller, J.L.</creatorcontrib><title>Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain</title><title>Neuroscience</title><addtitle>Neuroscience</addtitle><description>Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is known about their effects on the densities of these receptors when they are administered for extended periods of time (a common practice in the clinical setting). In the present study in rats, the residual effects of prior chronic exposure to representative first generation antipsychotics and second generation antipsychotics on the densities of high affinity nicotinic acetylcholine receptors and muscarinic acetylcholine receptor in the brain were investigated. Test subjects were treated with the first generation antipsychotics, haloperidol (2.0 mg/kg/day) or chlorpromazine (10.0 mg/kg/day) or the second generation antipsychotics, risperidone (2.5 mg/kg/day) or olanzapine (10.0 mg/kg/day) in drinking water for periods of 90 or 180 days, given a drug-free washout period (i.e. returned to normal drinking water) for two weeks and then killed. Quantitative receptor autoradiography was subsequently performed using 16 μm sagittal slices of whole brain incubated with [ 3H]-epibatidine, [ 3H]-pirenzepine or [ 3H]-AFDX-384 to measure high affinity nicotinic acetylcholine receptors, M 1 and M 2 muscarinic acetylcholine receptors, respectively. The most notable experimental result was a moderate, but significant ( P&lt;0.01) increase in [ 3H]-AFDX-384 binding sites in a number of brain regions (including cortex, hippocampus, subiculum, substantia innominata, and thalamus) associated with prior exposure to olanzapine for 90, but not 180 days. Olanzapine was also associated with a significantly higher density of [ 3H]-pirenzepine binding sites in cortex lamina I after 90 days of prior drug exposure. These data indicate that chronic treatment with a commonly used second generation antipsychotic, olanzapine is associated with modest increases in M 2 muscarinic acetylcholine receptors in memory-related brain regions that may eventually abate with longer periods of chronic drug exposure.</description><subject>Animals</subject><subject>Antipsychotic Agents - administration &amp; dosage</subject><subject>Biological and medical sciences</subject><subject>Brain - drug effects</subject><subject>Brain - metabolism</subject><subject>chlorpromazine</subject><subject>cognition</subject><subject>Fundamental and applied biological sciences. Psychology</subject><subject>haloperidol</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Neuropharmacology</subject><subject>olanzapine</subject><subject>Pharmacology. Drug treatments</subject><subject>Protein Binding - drug effects</subject><subject>Protein Binding - physiology</subject><subject>Psycholeptics: tranquillizer, neuroleptic</subject><subject>Psychology. Psychoanalysis. Psychiatry</subject><subject>Psychopharmacology</subject><subject>Rats</subject><subject>Rats, Wistar</subject><subject>Receptors, Muscarinic - metabolism</subject><subject>Receptors, Nicotinic - metabolism</subject><subject>risperidone</subject><subject>schizophrenia</subject><subject>Vertebrates: nervous system and sense organs</subject><issn>0306-4522</issn><issn>1873-7544</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2006</creationdate><recordtype>article</recordtype><recordid>eNqNkc2O1DAQhCMEYoeFV0AWEtwy-C9Osjc0LD_SSlzgbDmd9sajjD3YDmiehxfFw0RabuBLy9LXVa2qqnrF6JZRpt7utx6XGBI49IBbTqnaUrGljD2qNqxrRd02Uj6uNlRQVcuG86vqWUp7Wl4jxdPqiinFVQE31a_dFIN3QHJEkw_oM_np8kSsiymTEElCCH4k9-gxmuyCJ8Znd0wnmEJ2kIjzJIaxLKYbcmstQk6kUJO7n4ix1nmXT6Q4FPrsY4rYYUlg4uULmE9z0ZqdRxIR8JhD_KOaJyRDNM4_r55YMyd8sc7r6tuH26-7T_Xdl4-fd-_uapCiz7VCYGLkPXZ9K6DhILnFHgbbSjuC7Ax2RnSqHxhyNjQDiLZvFUcLncKht-K6enPRPcbwfcGU9cElwHk2HsOStOoU5Yx1_wRZy4VkTV_AmwsIpa4U0epjdAcTT5pRfe5S7_XfXepzl5oKXbosyy9Xl2U44PiwupZXgNcrYEqes43Gg0sPXNsrJuX53PcXDkt4PxxGvdqNrgSe9Rjc_9zzGxUGyWY</recordid><startdate>20060101</startdate><enddate>20060101</enddate><creator>Terry, A.V.</creator><creator>Gearhart, D.A.</creator><creator>Mahadik, S.P.</creator><creator>Warsi, S.</creator><creator>Waller, J.L.</creator><general>Elsevier Ltd</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TK</scope><scope>7X8</scope></search><sort><creationdate>20060101</creationdate><title>Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain</title><author>Terry, A.V. ; Gearhart, D.A. ; Mahadik, S.P. ; Warsi, S. ; Waller, J.L.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2006</creationdate><topic>Animals</topic><topic>Antipsychotic Agents - administration &amp; dosage</topic><topic>Biological and medical sciences</topic><topic>Brain - drug effects</topic><topic>Brain - metabolism</topic><topic>chlorpromazine</topic><topic>cognition</topic><topic>Fundamental and applied biological sciences. Psychology</topic><topic>haloperidol</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Neuropharmacology</topic><topic>olanzapine</topic><topic>Pharmacology. Drug treatments</topic><topic>Protein Binding - drug effects</topic><topic>Protein Binding - physiology</topic><topic>Psycholeptics: tranquillizer, neuroleptic</topic><topic>Psychology. Psychoanalysis. Psychiatry</topic><topic>Psychopharmacology</topic><topic>Rats</topic><topic>Rats, Wistar</topic><topic>Receptors, Muscarinic - metabolism</topic><topic>Receptors, Nicotinic - metabolism</topic><topic>risperidone</topic><topic>schizophrenia</topic><topic>Vertebrates: nervous system and sense organs</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Terry, A.V.</creatorcontrib><creatorcontrib>Gearhart, D.A.</creatorcontrib><creatorcontrib>Mahadik, S.P.</creatorcontrib><creatorcontrib>Warsi, S.</creatorcontrib><creatorcontrib>Waller, J.L.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Neurosciences Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Neuroscience</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Terry, A.V.</au><au>Gearhart, D.A.</au><au>Mahadik, S.P.</au><au>Warsi, S.</au><au>Waller, J.L.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain</atitle><jtitle>Neuroscience</jtitle><addtitle>Neuroscience</addtitle><date>2006-01-01</date><risdate>2006</risdate><volume>140</volume><issue>4</issue><spage>1277</spage><epage>1287</epage><pages>1277-1287</pages><issn>0306-4522</issn><eissn>1873-7544</eissn><coden>NRSCDN</coden><abstract>Several postmortem and neuroimaging studies suggest that central nicotinic and muscarinic acetylcholine receptors are important in both the pathophysiology and pharmacotherapy of schizophrenia. However, while antipsychotic drugs are routinely used in the therapeutics of schizophrenia, little is known about their effects on the densities of these receptors when they are administered for extended periods of time (a common practice in the clinical setting). In the present study in rats, the residual effects of prior chronic exposure to representative first generation antipsychotics and second generation antipsychotics on the densities of high affinity nicotinic acetylcholine receptors and muscarinic acetylcholine receptor in the brain were investigated. Test subjects were treated with the first generation antipsychotics, haloperidol (2.0 mg/kg/day) or chlorpromazine (10.0 mg/kg/day) or the second generation antipsychotics, risperidone (2.5 mg/kg/day) or olanzapine (10.0 mg/kg/day) in drinking water for periods of 90 or 180 days, given a drug-free washout period (i.e. returned to normal drinking water) for two weeks and then killed. Quantitative receptor autoradiography was subsequently performed using 16 μm sagittal slices of whole brain incubated with [ 3H]-epibatidine, [ 3H]-pirenzepine or [ 3H]-AFDX-384 to measure high affinity nicotinic acetylcholine receptors, M 1 and M 2 muscarinic acetylcholine receptors, respectively. The most notable experimental result was a moderate, but significant ( P&lt;0.01) increase in [ 3H]-AFDX-384 binding sites in a number of brain regions (including cortex, hippocampus, subiculum, substantia innominata, and thalamus) associated with prior exposure to olanzapine for 90, but not 180 days. Olanzapine was also associated with a significantly higher density of [ 3H]-pirenzepine binding sites in cortex lamina I after 90 days of prior drug exposure. These data indicate that chronic treatment with a commonly used second generation antipsychotic, olanzapine is associated with modest increases in M 2 muscarinic acetylcholine receptors in memory-related brain regions that may eventually abate with longer periods of chronic drug exposure.</abstract><cop>Oxford</cop><pub>Elsevier Ltd</pub><pmid>16626873</pmid><doi>10.1016/j.neuroscience.2006.03.011</doi><tpages>11</tpages></addata></record>
fulltext fulltext
identifier ISSN: 0306-4522
ispartof Neuroscience, 2006-01, Vol.140 (4), p.1277-1287
issn 0306-4522
1873-7544
language eng
recordid cdi_proquest_miscellaneous_68602118
source ScienceDirect Freedom Collection 2022-2024
subjects Animals
Antipsychotic Agents - administration & dosage
Biological and medical sciences
Brain - drug effects
Brain - metabolism
chlorpromazine
cognition
Fundamental and applied biological sciences. Psychology
haloperidol
Male
Medical sciences
Neuropharmacology
olanzapine
Pharmacology. Drug treatments
Protein Binding - drug effects
Protein Binding - physiology
Psycholeptics: tranquillizer, neuroleptic
Psychology. Psychoanalysis. Psychiatry
Psychopharmacology
Rats
Rats, Wistar
Receptors, Muscarinic - metabolism
Receptors, Nicotinic - metabolism
risperidone
schizophrenia
Vertebrates: nervous system and sense organs
title Chronic treatment with first or second generation antipsychotics in rodents: Effects on high affinity nicotinic and muscarinic acetylcholine receptors in the brain
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-01T08%3A35%3A09IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Chronic%20treatment%20with%20first%20or%20second%20generation%20antipsychotics%20in%20rodents:%20Effects%20on%20high%20affinity%20nicotinic%20and%20muscarinic%20acetylcholine%20receptors%20in%20the%20brain&rft.jtitle=Neuroscience&rft.au=Terry,%20A.V.&rft.date=2006-01-01&rft.volume=140&rft.issue=4&rft.spage=1277&rft.epage=1287&rft.pages=1277-1287&rft.issn=0306-4522&rft.eissn=1873-7544&rft.coden=NRSCDN&rft_id=info:doi/10.1016/j.neuroscience.2006.03.011&rft_dat=%3Cproquest_cross%3E68602118%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c439t-6ec13d29e8973c52c42fe9cbf74fdc48ae8a3869b1e21b5bc379762efc86eb9f3%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=17234159&rft_id=info:pmid/16626873&rfr_iscdi=true